Company Overview
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Company Information
- CEO
- Mark J. Foley
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 597
Contact Information
- Website
- https://www.revance.com
- Address
- 1222 Demonbreun Street
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 381.02M market capitalization
- Trading Volume: 0 shares traded today
- Price Range: 52-week range of $2.30 - $7.56
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Revance Therapeutics, Inc.
Revance Therapeutics, Inc. (RVNC) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 381.02M, the company represents a significant player in its market. The stock is currently trading at $3.65 with a positivedaily change of 0.00%.
The company's 597 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.09, beta of 0.95, and 52-week price range from $2.30 to $7.56when evaluating investment opportunities.
Why Invest in Revance Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Mark J. Foley
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.